Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2019 to Aug 2024
![Click Here for more Affymetrix Charts. Click Here for more Affymetrix Charts.](/p.php?pid=staticchart&s=N%5EAFFX&p=8&t=15)
Affymetrix, Inc. (Nasdaq:AFFX) today announced that based on preliminary
financial data, the Company expects fourth quarter total revenue of
approximately $100 million.
"During the fourth quarter, we delivered important new products to
customers and announced several exciting commercial agreements," said
Stephen P.A. Fodor, chairman and chief executive officer. "It was a
quarter of solid performance."
The Company will release fourth quarter and year end 2006 operating
results after the close of the market on February 7, 2007. Company
management will conduct its quarterly conference call for fiscal year
2007 at 2:00 p.m. Pacific Time.
About Affymetrix
Affymetrix scientists invented the world's first high-density microarray
in 1989 and began selling the first commercial microarray in 1994. Since
then, Affymetrix GeneChip® technology has
become the industry standard in molecular biology research. Affymetrix
technology is used by the world's top pharmaceutical, diagnostic and
biotechnology companies as well as leading academic, government and
not-for-profit research institutes. More than 1,400 systems have been
installed around the world and more than 7,000 peer-reviewed papers have
been published using the technology. Affymetrix' patented
photolithographic manufacturing process provides the most information
capacity available today on an array, enabling researchers to use a
whole-genome approach to analyzing the relationship between genetics and
health. Affymetrix is headquartered in Santa Clara, Calif., with
manufacturing facilities in Sacramento, Calif., Bedford, Mass., and
Singapore. The company maintains important sales and marketing
operations in Europe and Asia and has about 1,100 employees worldwide.
For more information about Affymetrix, please visit the company's
website at www.affymetrix.com.
All statements in this press release that are not historical are
"forward-looking statements" under the federal securities laws. Such
statements, including Affymetrix' expectations for its fourth quarter
and year end 2006 results, are subject to risks and uncertainties that
could cause actual results to differ materially for Affymetrix from
those projected, including but not limited to: the preparation of
financial statements for the fourth quarter and full-year 2006;
risks related to the Company's ability to achieve and sustain higher
levels of revenue and improved gross margins and operating income and
reduced operating expenses (including risks related to the outcome of
the Company's previously announced efforts to reduce expenses in the
general and administrative functions including the rationalization of
the Company's facilities); uncertainties relating to technological
approaches, manufacturing (including risks related to resolving any
manufacturing problems) and product development; uncertainties relating
to changes in senior management personnel and structure; uncertainties
related to cost and pricing of Affymetrix products; risks relating to
dependence on collaborative partners; uncertainties relating to sole
source suppliers; uncertainties relating to FDA and other regulatory
approvals; competition; risks relating to intellectual property of
others and the uncertainties of patent protection; and risks relating to
intellectual property and other litigation. These and other risk factors
are discussed in Affymetrix' Form 10-K/A for the year ended December 31,
2005 and other SEC reports, including reports on Form 10-Q and Form
10-Q/A for subsequent periods. Affymetrix expressly disclaims any
obligation or undertaking to release publicly any updates or revisions
to any forward-looking statements contained herein to reflect any change
in Affymetrix' expectations or any change in events, conditions, or
circumstances on which any such statements are based.